Comparing the current results to its competitors, Quantum Cyber N V reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, slower than the combined decrease of the MYNZ's competitors by -10.07 %, recorded in the same quarter.
March 5, 2024
Mainz Biomed Collaborates with Trusted Health Advisors to Revolutionize Early Colorectal Cancer Diagnosis and Employee Healthcare In a groundbreaking move towards transforming colorectal cancer (CRC) diagnosis and improving employee healthcare, Mainz Biomed has formed strategic partnerships with both Trusted Health Advisors and Bantleon. By joining forces with these organizations, Mainz Biomed aims to enhance its go-to-market strategy for its next-generation early colorectal cancer diagnostic and provide comprehensive corporate health solutions through an innovative CRC screening program.Mainz Biomed s state-of-the-art early colorectal cancer diagnostic represents a new era in the battle against this prevale...
February 21, 2024
Mainz Biomed Collaborates with TomaLab to Enhance Availability of ColoAlert in Italy In an effort to improve colorectal cancer detection rates and expand the availability of its pioneering diagnostic tool, ColoAlert, Mainz Biomed has recently established a strategic partnership with TomaLab. This collaboration aims to provide broader access to ColoAlert across Italy and ultimately contribute towards the early detection and improved treatment outcomes for colorectal cancer patients in the region.Colorectal cancer is a significant global health concern, and early diagnosis plays a crucial role in reducing mortality rates associated with this disease. ColoAlert, developed by Mainz Biomed, is a cutting-edge diag...
December 19, 2023
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees Mainz Biomed N.V., a leading healthcare company specializing in innovative diagnostic solutions, has announced a partnership with Bantleon, a renowned financial services provider, to enhance corporate health through the implementation of the second phase of their colorectal cancer (CRC) screening program for employees. This groundbreaking collaboration aims to improve the overall well-being and early detection of CRC among Mainz Biomed s workforce. Colorectal cancer is one of the most prevalent and deadly forms of cancer globally, with approximately 1.8 million new cases diagnosed ea...
In a recent groundbreaking study, Mainz Biomed N.V. announced positive topline results from the U.S. eAArly DETECT study, validating the efficacy of their novel mRNA biomarkers. These results have positioned Mainz Biomed as a leading innovator in the field of biomedical research and offer promising implications for the early detection and diagnosis of various diseases. The U.S. eAArly DETECT study evaluated the effectiveness of Mainz Biomed s mRNA biomarkers in identifying potential health risks. This study, conducted on a large scale under rigorous protocols, successfully demonstrated the ability of these biomarkers to accurately identify and monitor the presence of specific disease markers, a...
Accustem Sciences Inc is a company that operates on a subscription-based business model with a focus on providing personalized health solutions. They offer genetic testing services and use the results to create customized plans, including nutrition and exercise recommendations, to improve overall health and prevent diseases. The company aims to enhance the well-being of individuals by leveraging genetic insights and promoting proactive health management.
builds safe, trusted, easy-to-use technology and financial infrastructure products and services that enable any person or business with an internet connection to discover, transact, and engage with crypto assets
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Guardant Health Inc's business model revolves around providing advanced genomic testing services for cancer patients. It specializes in developing liquid biopsy tests that analyze circulating tumor DNA (ctDNA) in the blood. These tests help in early cancer detection, treatment selection, and monitoring of cancer progression. Guardant Health Inc collaborates with healthcare providers, pharmaceutical companies, and researchers to provide these innovative tests and contribute to the advancement of precision medicine in oncology.
Sources:
Quantum Cyber N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Quantum Cyber N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
